Evidence map›Paper›PMID 39956874›Full record

Observational studyEuropean journal of human genetics : EJHG2025

An observational study of pleiotropy and penetrance of amyotrophic lateral sclerosis associated with CAG-repeat expansion of ATXN2.

Koen C Demaegd, Aoife Kernan, Johnathan Cooper-Knock, Joke J F A van Vugt, Calum Harvey, Tobias Moll, David O'Brien, Sarah Gornall, Luke Drury, Sali M K Farhan and 20 more

Abstract readObservational Study
In one paragraph

Observational study in European journal of human genetics : EJHG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Neurology. Genetics · 2026
    Article
  2. Article
  3. Article
  4. What's new in EJHG this autumn.European journal of human genetics : EJHG · 2025
    Article
  5. Penetrance and pleiotropy in ATXN2-related amyotrophic lateral sclerosis.European journal of human genetics : EJHG · 2025
    Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors.

Koen C Demaegd *Department of Neurology, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0001-9606-0531
Aoife Kernan *Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.ORCID 0009-0001-3168-1262
Johnathan Cooper-Knock *Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK. j.cooper-knock@sheffield.ac.uk.ORCID 0000-0002-0873-8689
Joke J F A van VugtDepartment of Neurology, Utrecht University, Utrecht, The Netherlands.
Calum HarveySheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.
Tobias MollSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.ORCID 0000-0001-5928-2514
David O'BrienSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.
Sarah GornallSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.
Luke DruryPreventionGenetics, Part of Exact Sciences, Marshfield, WI, USA.
Sali M K FarhanPreventionGenetics, Part of Exact Sciences, Marshfield, WI, USA.
Patrick A DionMontreal Neurological Institute-Hospital, McGill University, Montreal, QC, Canada.
Guy A RouleauMontreal Neurological Institute-Hospital, McGill University, Montreal, QC, Canada.ORCID 0000-0001-8403-1418
Andrea WesternSheffield Children's NHS Foundation Trust, Sheffield, UK.
Paul J ParsonsSheffield Children's NHS Foundation Trust, Sheffield, UK.
Benjamin McleanUniversity of North Carolina, Chapel Hill, NC, USA.
Michael BenatarUniversity of Miami, Miller School of Medicine, Coral Gables, FL, USA.
Leonard H van den BergDepartment of Neurology, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0002-6559-3965
Philip Van DammeNeurology Department, University of Leuven (KU Leuven), Leuven, Belgium.ORCID 0000-0002-4010-2357
Jan Willem DankbaarDepartment of Radiology and Nuclear Medicine, Utrecht University, Utrecht, The Netherlands.
Jeroen HendrikseDepartment of Radiology and Nuclear Medicine, Utrecht University, Utrecht, The Netherlands.
Wouter KooleDepartment of Genetics, Utrecht University, Utrecht, The Netherlands.
Charlotte de BieDepartment of Genetics, Utrecht University, Utrecht, The Netherlands.
Esther HobsonSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.
Jan H VeldinkDepartment of Neurology, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0001-5572-9657
Bart van de WarrenburgDepartment of Neurology, Radboud University, Nijmegen, the Netherlands.
R Jeroen PasterkampDepartment of Translational Neuroscience, Utrecht University, Utrecht, The Netherlands.
Wouter van RheenenDepartment of Neurology, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0002-5860-1533
Janine KirbySheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.ORCID 0000-0002-7468-5917
Pamela J ShawSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.
Michael A van EsDepartment of Neurology, Utrecht University, Utrecht, The Netherlands. M.A.vanEs@umcutrecht.nl.ORCID 0000-0002-7709-5883

Funding

Uncovering new genes and disease modifiers for ALS and related disordersU54NS092091 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Corey T McMillan · 2014 to 2026
$19.8M
Motor Neurone Disease Association (MNDA) 899-792Motor Neurone Disease Association (MNDA) 972-797Motor Neurone Disease Association (MNDA) 974-797NINDS NIH HHS U54 NS092091Wellcome TrustWellcome Trust (Wellcome) 216596/Z/19/Z
6 · The paper itself

Abstract

Spinocerebellar ataxia type 2 (SCA2) and amyotrophic lateral sclerosis (ALS) are both associated with a CAG-repeat expansion in ATXN2 and with TDP-43-positive neuronal cytoplasmic inclusions. The two disorders have been viewed as distinct entities, where an intermediate length expansion of 31-33 CAG-repeats is associated with sporadic ALS and a full length expansion of ≥34 CAG-repeats is associated with SCA2. We report the clinical phenotype of ATXN2-positive patients and their relatives, identified in three specialist ALS clinics, which force a reconsideration of this dichotomy. We also report the frequency of ATXN2 expansions in two large cohorts of ALS patients and in a population-matched cohort of controls. We report ten cases of familial ALS in which disease is associated with either an intermediate or a full-length ATXN2 CAG-repeat expansion. Pedigrees and patients feature additional phenotypes including parkinsonism, dementia and essential tremor (ET). We conclude that CAG-repeat expansions in ATXN2 exhibit pleiotropy and are associated with a disease spectrum that includes ALS, SCA2, and parkinsonism; to recognise this complexity we propose the new term 'ATXN2-related neurodegeneration'. We also observed sporadic ALS associated with full-length expansions. We conclude that ATXN2 CAG-repeat expansions, irrespective of length, should be considered a risk factor for ALS. Interrupted CAG-repeats were associated with an ALS phenotype in our data but we also identified ALS cases with uninterrupted expansions. Our findings have relevance for researchers, patients and families linked to CAG-repeat expansions in ATXN2.

Indexed as

Amyotrophic Lateral SclerosisAtaxin-2Genetic PleiotropyPenetranceTrinucleotide Repeat ExpansionAdultAgedFemaleHumansMaleMiddle AgedPedigreePhenotypeSpinocerebellar AtaxiasAtaxin-2ATXN2 protein, human

Identifiers

PMID39956874
PMCPMC12402128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.